Almirall SA has unveiled the first sales for its closely-watched atopic dermatitis drug Ebglyss and the Spanish firm is pleased with the initial launch data on a drug which will be key to the firm's future prospects.
Ebglyss (lebrikizumab), which obtained EU and UK approval at the end of 2023 for moderate-to-severe atopic dermatitis, had sales of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?